- Home
- TPIC vs TIL Comparison
TPIC vs TIL Comparison
Compare TPIC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- TIL
- Stock Information
- Founded
- TPIC 1968
- TIL 2018
- Country
- TPIC United States
- TIL United States
- Employees
- TPIC 12300
- TIL N/A
- Industry
- TPIC Industrial Machinery/Components
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- TIL Health Care
- Exchange
- TPIC Nasdaq
- TIL Nasdaq
- Market Cap
- TPIC 57.1M
- TIL 170.7M
- IPO Year
- TPIC 2016
- TIL 2021
- Fundamental
- Price
- TPIC $1.21
- TIL $20.92
- Analyst Decision
- TPIC Hold
- TIL Buy
- Analyst Count
- TPIC 5
- TIL 4
- Target Price
- TPIC $3.36
- TIL $100.33
- AVG Volume (30 Days)
- TPIC 1.2M
- TIL 107.5K
- Earning Date
- TPIC 11-07-2024
- TIL 11-13-2024
- Dividend Yield
- TPIC N/A
- TIL N/A
- EPS Growth
- TPIC N/A
- TIL N/A
- EPS
- TPIC N/A
- TIL N/A
- Revenue
- TPIC $1,301,740,000.00
- TIL N/A
- Revenue This Year
- TPIC N/A
- TIL N/A
- Revenue Next Year
- TPIC $16.79
- TIL $2.65
- P/E Ratio
- TPIC N/A
- TIL N/A
- Revenue Growth
- TPIC N/A
- TIL N/A
- 52 Week Low
- TPIC $1.21
- TIL $6.72
- 52 Week High
- TPIC $5.75
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- TPIC 26.09
- TIL 36.47
- Support Level
- TPIC $1.21
- TIL $20.57
- Resistance Level
- TPIC $1.42
- TIL $22.69
- Average True Range (ATR)
- TPIC 0.18
- TIL 2.72
- MACD
- TPIC 0.01
- TIL -0.23
- Stochastic Oscillator
- TPIC 5.77
- TIL 2.98
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.